Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,243 | -66,018 | -43,363 | -18,867 | -32,947 |
| Depreciation Amortization | 213 | 598 | 395 | 187 | 668 |
| Other Working Capital | -356 | 5,028 | 7,052 | 1,914 | -2,630 |
| Other Operating Activity | 2,825 | 14,937 | 9,580 | 4,565 | 3,713 |
| Operating Cash Flow | $-17,561 | $-45,455 | $-26,336 | $-12,201 | $-31,196 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -39,971 | N/A | N/A | N/A |
| PPE Investments | -55 | -822 | -735 | -35 | -917 |
| Investing Cash Flow | $-55 | $-40,793 | $-735 | $-35 | $-917 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 169 | 1,185 | 1,037 | 222 | 258,461 |
| Other Financing Activity | 52,989 | -846 | -846 | -350 | 150,045 |
| Financing Cash Flow | $53,158 | $339 | $191 | $-128 | $408,506 |
| Beginning Cash Position | 24,521 | 386,919 | 386,919 | 386,919 | 10,526 |
| End Cash Position | 60,063 | 301,010 | 360,039 | 374,555 | 386,919 |
| Net Cash Flow | $35,542 | $-85,909 | $-26,880 | $-12,364 | $376,393 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,561 | -45,455 | -26,336 | -12,201 | -31,196 |
| Capital Expenditure | -55 | -822 | -735 | -35 | -917 |
| Free Cash Flow | -17,616 | -46,277 | -27,071 | -12,236 | -32,113 |